Loading…

Interference of cationic polymeric nanoparticles with clinical chemistry tests—Clinical relevance

[Display omitted] The development of medical nanosystems requires knowledge of their behavior in vivo. Clinical chemistry tests are widely used to estimate the systemic toxicity of nanoparticles. In this paper we have explored the impact of small positively charged nanoparticles–poly(amidoamine), ph...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2014-10, Vol.473 (1-2), p.599-606
Main Authors: Shcharbin, Dzmitry, Shcharbina, Natallia, Milowska, Katarzyna, de la Mata, Francisco Javier, Muñoz-Fernandez, Maria Angeles, Mignani, Serge, Gomez-Ramirez, Rafael, Majoral, Jean-Pierre, Bryszewska, Maria
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The development of medical nanosystems requires knowledge of their behavior in vivo. Clinical chemistry tests are widely used to estimate the systemic toxicity of nanoparticles. In this paper we have explored the impact of small positively charged nanoparticles–poly(amidoamine), phosphorous and carbosilane dendrimers – on biochemical parameters of standardized serum in vitro. All the dendrimers could shift the main biochemical parameters. Thus, in the case of patients having the normal, but ‘boundary’, values of biochemical parameters, nanoparticle-induced changes can be wrongly interpreted as evidence of some dysfunctions (hepatic, renal, etc.). Moreover, the effects of nanoparticles of metals, carbon nanotubes, quantum dots, fullerenes, dendrimers having been sized up to 4000nm and the hundreds of reactive groups, can be significantly higher. Thus, preliminary evaluation of any nanomaterial in vitro is required in clinical chemistry tests before its application in vivo to draw the correct conclusions and benefit animals.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2014.07.054